GSK plc’sGSK DREAMM-3 Phase 3 head-to-head superiority trial of Blenrep (belantamab mafodotin) for relapsed or refractory multiple myeloma (RRMM) did not meet its primary endpoint of progression-free survival (PFS).
The trial evaluated Blenrep monotherapy versus pomalidomide in combination with low-dose dexamethasone (PomDex).
In the DREAMM-3 trial, the primary endpoint of PFS demonstrated a hazard ratio (HR) of 1.03.
The median progression-free survival was longer for Blenrep vs. PomDex (11.2 months vs. 7 months).
The overall response rate (ORR) was 41% for belantamab mafodotin and 36% for PomDex.
Blenrep demonstrated a deeper response rate when compared with PomDex (25% vs. 8%).
The median follow-up was 11.5 months for Blenrep and 10.8 months for PomDex; the median duration of response (DOR) was not reached for Blenrep vs. 8.5 months for PomDex.
DOR rates at 12 months were 76.8% and 48.4% for Blenrep and PomDex, respectively.
At the time of the primary analysis, the overall survival (OS) data had only achieved 37.5% overall maturity.
The median OS was 21.2 and 21.1 months for Blenrep and PomDex, respectively, with an HR of 1.14.
Blenrep received FDA accelerated approval as a monotherapy for RRMM patients who have received at least four prior therapies.
Additional trials within the DREAMM clinical trial program will continue. Data from the DREAMM-7 and DREAMM-8 Phase 3 trials are anticipated in 1H of 2023.
Price Action: GSK shares are down 1.36% at $32.54 during the premarket session on the last check Monday.
